Dataset analysis reveals 9659 early-phase oncology trials spanning 1994-2026 with comprehensive tables and figures
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T01:50:58.166Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"discovery","obs_id":65256}
obs/65256 · discovery · 2026-05-04T01:50:58.166Z
Dataset analysis reveals 9659 early-phase oncology trials spanning 1994-2026 with comprehensive tables and figures
Characterized complete manuscript dataset revealing comprehensive landscape of early-phase oncology trials over three decades. The 9659-trial cohort shows clear temporal trends with dramatic recent growth (2020-2026 era contains 3727 trials vs 2391 in pre-2010 era) and shifting geographic distribution (China grew from 23 pre-2010 trials to 1367 in 2020-2026). The dual FIH classification system (strict title-based vs enriched design-based) provides methodological transparency for identifying true first-in-human studies within the broader early-phase landscape. Modality analysis captures the immune-oncology revolution (checkpoint inhibitors emerging post-2010) and recent therapeutic innovations (PD-1/VEGF bispecifics, targeted degraders appearing 2020+). The 88% validation rate for top-40 site matches confirms data quality and site canonicalization accuracy. Generated publication-ready materials include era-stratified sponsor analysis, country/site rankings, modality trends, and validation metrics formatted for Journal of Hematology and Oncology submission standards with both vector PDF and high-resolution PNG outputs.
Concepts: [“how-it-works”,“what-changed”]
Facts: [“Dataset contains 9659 trials with start year data from 1994-2026, peak years 2025 (582 trials) and 2021 (586 trials)”,“Identified 1004 strict first-in-human trials (10.4%) and 4883 FIH-enriched trials (50.6%) using title-based classification”,“Trial status distribution: 4585 completed, 1627 recruiting, 1414 terminated, 792 unknown, 656 active-not-recruiting”,“Geographic analysis covers 15 countries with United States leading at 5591 trials, China second with 1706 trials”,“Site ranking identifies MD Anderson Cancer Center as top site with 1149 trial participations”,“Modality tracking shows checkpoint inhibitors (1194 trials), cell therapy (359), bispecifics (244), and ADCs (234)”,“Generated 6 CSV tables and 5 publication figures in both PDF and PNG formats totaling ~800KB”,“Data freeze document captures reproducibility methodology with query details and classification criteria”]
[← 回 Alfred Brain Hub]